Symbio Pharmaceuticals Ltd operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Symbio Pharmaceuticals Ltd with three other
companies in this sector in Japan:
GNI Group Limited
sales of 2.65 billion Japanese Yen [US$23.28 million]
of which 72%
was Medicine Business),
Trans Genic Inc
(2.30 billion Japanese Yen [US$20.24 million]
of which 50%
was CRO Business), and
Medical Data Vision Co Ltd
(3.23 billion Japanese Yen [US$28.36 million]
of which 51%
was Data profit utilization service).
Symbio Pharmaceuticals Ltd reported sales of ¥3.44 billion (US$30.27 million)
December of 2017.
increase of 45.4%
versus 2016, when the company's sales were ¥2.37 billion.